• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Analysis of Genomic Instability in Drug-Resistant Prostate Cancer and Novel Therapeutic Strategies Using Synthetic Lethality

Research Project

Project/Area Number 21K09436
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56030:Urology-related
Research InstitutionKeio University

Principal Investigator

Hongo Hiroshi  慶應義塾大学, 医学部(信濃町), 訪問研究員 (10626675)

Co-Investigator(Kenkyū-buntansha) 小坂 威雄  慶應義塾大学, 医学部(信濃町), 講師 (30445407)
安水 洋太  慶應義塾大学, 医学部(信濃町), 助教 (40464854)
Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2023: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2022: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2021: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords去勢抵抗性前立腺癌 / DNA損傷応答 / タキサン系抗癌剤耐性 / DNA修復経路 / 薬剤スクリーニング / DN修復経路 / 抗癌剤耐性 / 次世代シーケンサー
Outline of Research at the Start

去勢抵抗性前立腺癌(CRPC)に対する有効な治療は少なく、新規抗癌剤カバジタキセル等も近年使用され始めているが、その生命予後延長効果は数か月程度である。DNA損傷応答関連遺伝子は種々の癌で発がんならびに難治性との関連を認め、PARP阻害剤が前立腺癌の新規治療薬として注目されているが、欧米における実臨床では既に耐性化が問題となっている。本研究では、抗癌剤耐性前立腺癌細胞株においてクロマチン不安定性を認めることに着目し、前立腺癌臨床検体のシングルセル解析からDNA損傷応答との合成致死を利用した新規治療戦略を追求することを目的としている。

Outline of Final Research Achievements

Effective treatments for castration-resistant prostate cancer (CRPC) are limited, and the new drug cabazitaxel extends life expectancy by only a few months. This study focused on DNA damage response-related genes and chromatin instability in drug-resistant prostate cancer cell lines to pursue new therapeutic strategies. We analyzed the gene expression profiles of cabazitaxel-resistant prostate cancer cell lines and screened for compounds that inversely correlate with the changes due to resistance. As a result, we identified three drugs that have the ability to reprogram the gene profiles of drug-resistant prostate cancer cells.

Academic Significance and Societal Importance of the Research Achievements

CRPCに対する有効な治療法が限られている中で、本研究は薬剤耐性のメカニズムを解明し、新たな治療戦略を提案するものである。特に、カバジタキセル耐性前立腺癌細胞株の遺伝子発現パターンの変化に注目し、臨床で使用可能な既存の化合物の中から難治性CRPCに有効性を示す薬剤を3種同定したことは重要である。これらの薬剤は既に臨床使用の実績があり、前立腺癌治療薬としての応用が容易であるため、臨床への橋渡しがスムーズに行える可能性が高く、学術的および社会的に有望な成果である。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (6 results)

All 2023 2022 2021

All Journal Article (6 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 6 results,  Open Access: 5 results)

  • [Journal Article] G-protein signaling of oxytocin receptor as a potential target for cabazitaxel-resistant prostate cancer2023

    • Author(s)
      Hongo Hiroshi、Kosaka Takeo、Takayama Ken-Ichi、Baba Yuto、Yasumizu Yota、Ueda Koji、Suzuki Yutaka、Inoue Satoshi、Beltran Himisha、Oya Mototsugu
    • Journal Title

      PNAS Nexus

      Volume: 3 Issue: 1 Pages: 002-002

    • DOI

      10.1093/pnasnexus/pgae002

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation2022

    • Author(s)
      Hongo Hiroshi、Kosaka Takeo、Nakamura Kohei、Mikami Shuji、Nishihara Hiroshi、Oya Mototsugu
    • Journal Title

      Asian Journal of Urology

      Volume: 9 Issue: 4 Pages: 480-482

    • DOI

      10.1016/j.ajur.2022.02.002

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Germline BRCA2 mutation in a case of aggressive prostate cancer accompanied by spinal bulbar muscular atrophy2022

    • Author(s)
      Kosaka Takeo、Hongo Hiroshi、Hayashi Hideyuki、Nakamura Kohei、Nishihara Hiroshi、Mikami Shuji、Beltran Himisha、Oya Mototsugu
    • Journal Title

      Asian Journal of Andrology

      Volume: 24 Issue: 1 Pages: 116-116

    • DOI

      10.4103/aja.aja_37_21

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening2021

    • Author(s)
      Hongo Hiroshi、Kosaka Takeo、Suzuki Yoko、Oya Mototsugu
    • Journal Title

      Prostate Cancer and Prostatic Diseases

      Volume: - Issue: 1 Pages: 59-66

    • DOI

      10.1038/s41391-021-00426-0

    • Related Report
      2022 Research-status Report 2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways.2021

    • Author(s)
      Hongo H, Kosaka T, Suzuki Y, Mikami S, Fukada J, Oya M.
    • Journal Title

      Scientific Report

      Volume: - Issue: 1 Pages: 1-10

    • DOI

      10.1038/s41598-021-01697-2

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] A long-term survivor of metastatic neuroendocrine prostate cancer treated with multimodal therapy: genetic consideration from next-generation sequencing2021

    • Author(s)
      Hongo Hiroshi、Kosaka Takeo、Nakatsuka Seishi、Oya Mototsugu
    • Journal Title

      International Cancer Conference Journal

      Volume: - Issue: 3 Pages: 174-180

    • DOI

      10.1007/s13691-021-00482-2

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi